Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4072724 | 0.92 | NTRK1 (0.61) | NTRK1 | |
| SCHEMBL4072146 | 0.90 | NTRK1 (0.57) | NTRK1 | |
| SCHEMBL4068820 | 0.87 | NTRK1 (0.54) | NTRK1 | |
| SCHEMBL4151793 | 0.87 | NTRK1 (0.71) | NTRK1 | |
| SCHEMBL4070715 | 0.86 | NTRK1 (0.55) | NTRK1 | |
| SCHEMBL27654738 | 0.86 | NTRK1 (0.55) | NTRK1 | |
| SCHEMBL4071059 | 0.85 | NTRK1 (0.64) | NTRK1 | |
| SCHEMBL4068018 | 0.85 | NTRK1 (0.64) | NTRK1 | |
| SCHEMBL4068935 | 0.85 | NTRK1 (0.64) | NTRK1 | |
| SCHEMBL4073723 | 0.85 | NTRK1 (0.53) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1686999-B1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| EP-1877409-B1 | SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2009-06-17 | — | — | EP | disclosed |
| EP-1877409-A2 | SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF | Aventis Pharma S.A. (FR) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114520-A2 | SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2006-11-02 | — | — | WO | disclosed |